Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction

by Ruimin Hong, Ruimin Hong, Ruimin Hong, Ruimin Hong, Yongxian Hu, Yongxian Hu, Yongxian Hu, Yongxian Hu, He Huang, He Huang, He Huang, He Huang
Published 2021-02-01

Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib

by Hao Zhang, Yongxian Hu, Alex H. Chang, He Huang
Published 2020-06-01

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia

by Guoqing Wei, Lijuan Ding, Jiasheng Wang, Yongxian Hu, He Huang
Published 2017-04-01

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy

by Zuyu Liang, Jiazhen Cui, Alex Hongsheng Chang, Jian Yu, Yongxian Hu, He Huang
Published 2020-12-01

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy

by Lei Qiu, Feng Zhu, Guoqing Wei, Wenjun Wu, Luxin Yang, Yongxian Hu, He Huang
Published 2020-06-01

γδ T Cell and Other Immune Cells Crosstalk in Cellular Immunity

by Ying He, Kangni Wu, Yongxian Hu, Lixia Sheng, Ruxiu Tie, Binsheng Wang, He Huang
Published 2014-01-01

COVID-19 in Hematologic Malignancies: Big Challenges

by Yongxian Hu, Linqin Wang, Qu Cui, Elaine Tan Su Yin, Hengwei Wu, Arnon Nagler, He Huang
Published 2020-10-01

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

by Feng Zhu, Guoqing Wei, Mingming Zhang, Houli Zhao, Wenjun Wu, Luxin Yang, Yongxian Hu, He Huang
Published 2020-04-01

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies

by Feng Zhu, Guoqing Wei, Yandan Liu, Houli Zhou, Wenjun Wu, Luxin Yang, He Huang, Yongxian Hu
Published 2021-06-01

Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019

by Linghui Zhou, Qin Yu, Guoqing Wei, Linqin Wang, Yue Huang, Kejia Hu, Yongxian Hu, He Huang
Published 2021-05-01

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

by Yadan Liu, Yadan Liu, Yadan Liu, Bin Liang, Bin Liang, Bin Liang, Bin Liang, Yan Liu, Guoqing Wei, Guoqing Wei, Guoqing Wei, Wenjun Wu, Wenjun Wu, Wenjun Wu, Luxin Yang, Luxin Yang, Luxin Yang, Li Yang, Li Yang, Li Yang, He Huang, He Huang, He Huang, Jue Xie, Yongxian Hu, Yongxian Hu, Yongxian Hu
Published 2021-07-01

The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)

by Yafei Zhang, Guangfa Wang, Xin Zhao, Yongxian Hu, Elaine Tan Su Yin, Donghe Chen, Huatao Wang, Kui Zhao
Published 2021-10-01

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

by Linqin Wang, Linqin Wang, Linqin Wang, Linqin Wang, Ruimin Hong, Ruimin Hong, Ruimin Hong, Ruimin Hong, Linghui Zhou, Linghui Zhou, Linghui Zhou, Linghui Zhou, Fang Ni, Fang Ni, Fang Ni, Fang Ni, Mingming Zhang, Mingming Zhang, Mingming Zhang, Mingming Zhang, Houli Zhao, Houli Zhao, Houli Zhao, Houli Zhao, Wenjun Wu, Wenjun Wu, Wenjun Wu, Wenjun Wu, Yiyun Wang, Yiyun Wang, Yiyun Wang, Yiyun Wang, Shuyi Ding, Alex H. Chang, Yongxian Hu, Yongxian Hu, Yongxian Hu, Yongxian Hu, He Huang, He Huang, He Huang, He Huang
Published 2021-06-01

Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case r...

by Mengqi Jin, Yongxian Hu, Wenjun Wu, Yi Luo, Yamin Tan, Jian Yu, Aiyun Jin, Luxin Yang, He Huang, Guoqing Wei
Published 2019-03-01

Correction to: Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplant...

by Mengqi Jin, Yongxian Hu, Wenjun Wu, Yi Luo, Yamin Tan, Jian Yu, Aiyun Jin, Luxin Yang, He Huang, Guoqing Wei
Published 2019-05-01

mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2

by Binsheng Wang, Yu Lin, Yongxian Hu, Wei Shan, Senquan Liu, Yulin Xu, Hao Zhang, Shuyang Cai, Xiaohong Yu, Zhen Cai, He Huang
Published 2017-12-01

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

by Yongxian Hu, Jie Sun, Zhao Wu, Jian Yu, Qu Cui, Chengfei Pu, Bin Liang, Yi Luo, Jimin Shi, Aiyun Jin, Lei Xiao, He Huang
Published 2016-08-01

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

by Ruimin Hong, Ruimin Hong, Ruimin Hong, Ruimin Hong, Elaine Tan Su Yin, Elaine Tan Su Yin, Elaine Tan Su Yin, Elaine Tan Su Yin, Linqin Wang, Linqin Wang, Linqin Wang, Linqin Wang, Xin Zhao, Linghui Zhou, Linghui Zhou, Linghui Zhou, Linghui Zhou, Guangfa Wang, Mingming Zhang, Mingming Zhang, Mingming Zhang, Mingming Zhang, Houli Zhao, Houli Zhao, Houli Zhao, Houli Zhao, Guoqing Wei, Guoqing Wei, Guoqing Wei, Guoqing Wei, Yiyun Wang, Yiyun Wang, Yiyun Wang, Yiyun Wang, Wenjun Wu, Wenjun Wu, Wenjun Wu, Wenjun Wu, Yafei Zhang, Fang Ni, Fang Ni, Fang Ni, Fang Ni, Yongxian Hu, Yongxian Hu, Yongxian Hu, Yongxian Hu, He Huang, He Huang, He Huang, He Huang, Kui Zhao
Published 2021-08-01

Correction: Efficient Commitment to Functional CD34+ Progenitor Cells from Human Bone Marrow Mesenchymal Stem-Cell-Derived Induced Pluripotent Stem Cells

by Yulin Xu, Lizhen Liu, Lifei Zhang, Shan Fu, Yongxian Hu, Yingjia Wang, Huarui Fu, Kangni Wu, Haowen Xiao, Senquan Liu, Xiaohong Yu, Weiyan Zheng, Bo Feng, He Huang
Published 2012-01-01

Correction: Efficient Commitment to Functional CD34+ Progenitor Cells from Human Bone Marrow Mesenchymal Stem-Cell-Derived Induced Pluripotent Stem Cells.

by Yulin Xu, Lizhen Liu, Lifei Zhang, Shan Fu, Yongxian Hu, Yingjia Wang, Huarui Fu, Kangni Wu, Haowen Xiao, Senquan Liu, Xiaohong Yu, Weiyan Zheng, Bo Feng, He Huang
Published 2012-01-01